Treatment of stable angina pectoris by ivabradine in every day practice: The REDUCTION Study
Background The antianginal efficacy of ivabradine was studied in controlled clinical trials. Strict patient selection criteria may cause a discrepancy between the results of highly controlled clinical trials and everyday routine practice. The objective of this study was to evaluate the efficacy and...
Gespeichert in:
| Veröffentlicht in: | The American heart journal 2009-10, Vol.158 (4), p.e51-e57 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e57 |
|---|---|
| container_issue | 4 |
| container_start_page | e51 |
| container_title | The American heart journal |
| container_volume | 158 |
| creator | Köster, Ralf, MD Kaehler, Jan, MD Meinertz, Thomas, MD |
| description | Background The antianginal efficacy of ivabradine was studied in controlled clinical trials. Strict patient selection criteria may cause a discrepancy between the results of highly controlled clinical trials and everyday routine practice. The objective of this study was to evaluate the efficacy and safety of ivabradine in everyday routine practice. Methods In this multicenter study, 4,954 patients with stable angina pectoris received ivabradine in everyday routine practice and underwent follow-up for 4 months. The heart rate (HR), angina pectoris attacks, nitrate consumption, overall efficacy, and tolerance were evaluated. Results Within 4 months of treatment with ivabradine, HR was reduced by 12.4 ± 12.2 beat/min from 82.9 ± 15.3 to 70.4 ± 9.2 beat/min ( P < .0001). Angina pectoris attacks were reduced from 2.4 ± 3.1 to 0.4 ± 1.5 per week ( P < .0001). Consumption of short-acting nitrates was reduced from 3.3 ± 4.4 to 0.6 ± 1.6 U/wk ( P < .0001). Seventy-eight cases of adverse drug reactions were reported. The most common adverse drug reactions were nausea (n = 11, 0.22%) and dizziness (n = 9, 0.18%). Efficacy and tolerance were graded by physicians as being “excellent/very good” for 97% and 98% of the patients treated. Conclusion Ivabradine reduces the HR and is highly effective and well tolerated in the treatment of patients with symptomatic coronary artery disease. The results confirm the findings of controlled clinical trials in a broad patient population in everyday routine practice. |
| doi_str_mv | 10.1016/j.ahj.2009.06.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67668708</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002870309004505</els_id><sourcerecordid>67668708</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-b4e421e3febb09d6ddab7c17e25e26de96c76faea0acd1e28e0ff51007ca05cc3</originalsourceid><addsrcrecordid>eNp9kVGL1DAQx4Mo3nr6AXyRgOBb66RNk1bhQNZTDw4PvL03IaTJ1EvtpmvSLvTbm3UXDu7Bp2HgN39mfkPIawY5Aybe97m-7_MCoMlB5AD1E7Ji0MhMSM6fkhUAFFktoTwjL2LsUyuKWjwnZ6yRNeNQrsjPTUA9bdFPdOxonHQ7INX-l_Oa7tBMY3CRtgt1e90GbZ1H6jzFPYaFWr3QXdBmcgY_0M090h-Xn-_Wm6ub7_R2mu3ykjzr9BDx1amek7svl5v1t-z65uvV-tN1ZnjJp6zlyAuGZYdtC40V1upWGiaxqLAQFhthpOg0atDGMixqhK6rGIA0GipjynPy7pi7C-OfGeOkti4aHAbtcZyjElKIpKFO4NtHYD_OwafdFKuAC1aISiaKHSkTxhgDdmoX3FaHRTFQB_GqV0m8OohXIBT8S35zSp7bLdqHiZPpBHw8AphE7B0GFY1Db9C6kDwrO7r_xl88mjaD887o4TcuGB-uULFQoG4Pnz88HhoAXkFV_gUYDKgA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504612657</pqid></control><display><type>article</type><title>Treatment of stable angina pectoris by ivabradine in every day practice: The REDUCTION Study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Köster, Ralf, MD ; Kaehler, Jan, MD ; Meinertz, Thomas, MD</creator><creatorcontrib>Köster, Ralf, MD ; Kaehler, Jan, MD ; Meinertz, Thomas, MD ; for the REDUCTION Study Group ; REDUCTION Study Group</creatorcontrib><description>Background The antianginal efficacy of ivabradine was studied in controlled clinical trials. Strict patient selection criteria may cause a discrepancy between the results of highly controlled clinical trials and everyday routine practice. The objective of this study was to evaluate the efficacy and safety of ivabradine in everyday routine practice. Methods In this multicenter study, 4,954 patients with stable angina pectoris received ivabradine in everyday routine practice and underwent follow-up for 4 months. The heart rate (HR), angina pectoris attacks, nitrate consumption, overall efficacy, and tolerance were evaluated. Results Within 4 months of treatment with ivabradine, HR was reduced by 12.4 ± 12.2 beat/min from 82.9 ± 15.3 to 70.4 ± 9.2 beat/min ( P < .0001). Angina pectoris attacks were reduced from 2.4 ± 3.1 to 0.4 ± 1.5 per week ( P < .0001). Consumption of short-acting nitrates was reduced from 3.3 ± 4.4 to 0.6 ± 1.6 U/wk ( P < .0001). Seventy-eight cases of adverse drug reactions were reported. The most common adverse drug reactions were nausea (n = 11, 0.22%) and dizziness (n = 9, 0.18%). Efficacy and tolerance were graded by physicians as being “excellent/very good” for 97% and 98% of the patients treated. Conclusion Ivabradine reduces the HR and is highly effective and well tolerated in the treatment of patients with symptomatic coronary artery disease. The results confirm the findings of controlled clinical trials in a broad patient population in everyday routine practice.</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1016/j.ahj.2009.06.008</identifier><identifier>PMID: 19781403</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Aged ; Angina pectoris ; Angina Pectoris - diagnosis ; Angina Pectoris - drug therapy ; Angina Pectoris - physiopathology ; Benzazepines - administration & dosage ; Cardiovascular ; Coronary vessels ; Cyclic Nucleotide-Gated Cation Channels ; Dose-Response Relationship, Drug ; Electrocardiography ; Female ; Follow-Up Studies ; Germany ; Heart attacks ; Heart Rate - drug effects ; Humans ; Male ; Nitrates ; Prospective Studies ; Surveys and Questionnaires ; Time Factors ; Treatment Outcome</subject><ispartof>The American heart journal, 2009-10, Vol.158 (4), p.e51-e57</ispartof><rights>Mosby, Inc.</rights><rights>2009 Mosby, Inc.</rights><rights>Copyright Elsevier Limited Oct 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-b4e421e3febb09d6ddab7c17e25e26de96c76faea0acd1e28e0ff51007ca05cc3</citedby><cites>FETCH-LOGICAL-c434t-b4e421e3febb09d6ddab7c17e25e26de96c76faea0acd1e28e0ff51007ca05cc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002870309004505$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19781403$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Köster, Ralf, MD</creatorcontrib><creatorcontrib>Kaehler, Jan, MD</creatorcontrib><creatorcontrib>Meinertz, Thomas, MD</creatorcontrib><creatorcontrib>for the REDUCTION Study Group</creatorcontrib><creatorcontrib>REDUCTION Study Group</creatorcontrib><title>Treatment of stable angina pectoris by ivabradine in every day practice: The REDUCTION Study</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Background The antianginal efficacy of ivabradine was studied in controlled clinical trials. Strict patient selection criteria may cause a discrepancy between the results of highly controlled clinical trials and everyday routine practice. The objective of this study was to evaluate the efficacy and safety of ivabradine in everyday routine practice. Methods In this multicenter study, 4,954 patients with stable angina pectoris received ivabradine in everyday routine practice and underwent follow-up for 4 months. The heart rate (HR), angina pectoris attacks, nitrate consumption, overall efficacy, and tolerance were evaluated. Results Within 4 months of treatment with ivabradine, HR was reduced by 12.4 ± 12.2 beat/min from 82.9 ± 15.3 to 70.4 ± 9.2 beat/min ( P < .0001). Angina pectoris attacks were reduced from 2.4 ± 3.1 to 0.4 ± 1.5 per week ( P < .0001). Consumption of short-acting nitrates was reduced from 3.3 ± 4.4 to 0.6 ± 1.6 U/wk ( P < .0001). Seventy-eight cases of adverse drug reactions were reported. The most common adverse drug reactions were nausea (n = 11, 0.22%) and dizziness (n = 9, 0.18%). Efficacy and tolerance were graded by physicians as being “excellent/very good” for 97% and 98% of the patients treated. Conclusion Ivabradine reduces the HR and is highly effective and well tolerated in the treatment of patients with symptomatic coronary artery disease. The results confirm the findings of controlled clinical trials in a broad patient population in everyday routine practice.</description><subject>Aged</subject><subject>Angina pectoris</subject><subject>Angina Pectoris - diagnosis</subject><subject>Angina Pectoris - drug therapy</subject><subject>Angina Pectoris - physiopathology</subject><subject>Benzazepines - administration & dosage</subject><subject>Cardiovascular</subject><subject>Coronary vessels</subject><subject>Cyclic Nucleotide-Gated Cation Channels</subject><subject>Dose-Response Relationship, Drug</subject><subject>Electrocardiography</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Germany</subject><subject>Heart attacks</subject><subject>Heart Rate - drug effects</subject><subject>Humans</subject><subject>Male</subject><subject>Nitrates</subject><subject>Prospective Studies</subject><subject>Surveys and Questionnaires</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kVGL1DAQx4Mo3nr6AXyRgOBb66RNk1bhQNZTDw4PvL03IaTJ1EvtpmvSLvTbm3UXDu7Bp2HgN39mfkPIawY5Aybe97m-7_MCoMlB5AD1E7Ji0MhMSM6fkhUAFFktoTwjL2LsUyuKWjwnZ6yRNeNQrsjPTUA9bdFPdOxonHQ7INX-l_Oa7tBMY3CRtgt1e90GbZ1H6jzFPYaFWr3QXdBmcgY_0M090h-Xn-_Wm6ub7_R2mu3ykjzr9BDx1amek7svl5v1t-z65uvV-tN1ZnjJp6zlyAuGZYdtC40V1upWGiaxqLAQFhthpOg0atDGMixqhK6rGIA0GipjynPy7pi7C-OfGeOkti4aHAbtcZyjElKIpKFO4NtHYD_OwafdFKuAC1aISiaKHSkTxhgDdmoX3FaHRTFQB_GqV0m8OohXIBT8S35zSp7bLdqHiZPpBHw8AphE7B0GFY1Db9C6kDwrO7r_xl88mjaD887o4TcuGB-uULFQoG4Pnz88HhoAXkFV_gUYDKgA</recordid><startdate>20091001</startdate><enddate>20091001</enddate><creator>Köster, Ralf, MD</creator><creator>Kaehler, Jan, MD</creator><creator>Meinertz, Thomas, MD</creator><general>Mosby, Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20091001</creationdate><title>Treatment of stable angina pectoris by ivabradine in every day practice: The REDUCTION Study</title><author>Köster, Ralf, MD ; Kaehler, Jan, MD ; Meinertz, Thomas, MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-b4e421e3febb09d6ddab7c17e25e26de96c76faea0acd1e28e0ff51007ca05cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Angina pectoris</topic><topic>Angina Pectoris - diagnosis</topic><topic>Angina Pectoris - drug therapy</topic><topic>Angina Pectoris - physiopathology</topic><topic>Benzazepines - administration & dosage</topic><topic>Cardiovascular</topic><topic>Coronary vessels</topic><topic>Cyclic Nucleotide-Gated Cation Channels</topic><topic>Dose-Response Relationship, Drug</topic><topic>Electrocardiography</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Germany</topic><topic>Heart attacks</topic><topic>Heart Rate - drug effects</topic><topic>Humans</topic><topic>Male</topic><topic>Nitrates</topic><topic>Prospective Studies</topic><topic>Surveys and Questionnaires</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Köster, Ralf, MD</creatorcontrib><creatorcontrib>Kaehler, Jan, MD</creatorcontrib><creatorcontrib>Meinertz, Thomas, MD</creatorcontrib><creatorcontrib>for the REDUCTION Study Group</creatorcontrib><creatorcontrib>REDUCTION Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Köster, Ralf, MD</au><au>Kaehler, Jan, MD</au><au>Meinertz, Thomas, MD</au><aucorp>for the REDUCTION Study Group</aucorp><aucorp>REDUCTION Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of stable angina pectoris by ivabradine in every day practice: The REDUCTION Study</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2009-10-01</date><risdate>2009</risdate><volume>158</volume><issue>4</issue><spage>e51</spage><epage>e57</epage><pages>e51-e57</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>Background The antianginal efficacy of ivabradine was studied in controlled clinical trials. Strict patient selection criteria may cause a discrepancy between the results of highly controlled clinical trials and everyday routine practice. The objective of this study was to evaluate the efficacy and safety of ivabradine in everyday routine practice. Methods In this multicenter study, 4,954 patients with stable angina pectoris received ivabradine in everyday routine practice and underwent follow-up for 4 months. The heart rate (HR), angina pectoris attacks, nitrate consumption, overall efficacy, and tolerance were evaluated. Results Within 4 months of treatment with ivabradine, HR was reduced by 12.4 ± 12.2 beat/min from 82.9 ± 15.3 to 70.4 ± 9.2 beat/min ( P < .0001). Angina pectoris attacks were reduced from 2.4 ± 3.1 to 0.4 ± 1.5 per week ( P < .0001). Consumption of short-acting nitrates was reduced from 3.3 ± 4.4 to 0.6 ± 1.6 U/wk ( P < .0001). Seventy-eight cases of adverse drug reactions were reported. The most common adverse drug reactions were nausea (n = 11, 0.22%) and dizziness (n = 9, 0.18%). Efficacy and tolerance were graded by physicians as being “excellent/very good” for 97% and 98% of the patients treated. Conclusion Ivabradine reduces the HR and is highly effective and well tolerated in the treatment of patients with symptomatic coronary artery disease. The results confirm the findings of controlled clinical trials in a broad patient population in everyday routine practice.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>19781403</pmid><doi>10.1016/j.ahj.2009.06.008</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-8703 |
| ispartof | The American heart journal, 2009-10, Vol.158 (4), p.e51-e57 |
| issn | 0002-8703 1097-6744 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67668708 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Angina pectoris Angina Pectoris - diagnosis Angina Pectoris - drug therapy Angina Pectoris - physiopathology Benzazepines - administration & dosage Cardiovascular Coronary vessels Cyclic Nucleotide-Gated Cation Channels Dose-Response Relationship, Drug Electrocardiography Female Follow-Up Studies Germany Heart attacks Heart Rate - drug effects Humans Male Nitrates Prospective Studies Surveys and Questionnaires Time Factors Treatment Outcome |
| title | Treatment of stable angina pectoris by ivabradine in every day practice: The REDUCTION Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A05%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20stable%20angina%20pectoris%20by%20ivabradine%20in%20every%20day%20practice:%20The%20REDUCTION%20Study&rft.jtitle=The%20American%20heart%20journal&rft.au=K%C3%B6ster,%20Ralf,%20MD&rft.aucorp=for%20the%20REDUCTION%20Study%20Group&rft.date=2009-10-01&rft.volume=158&rft.issue=4&rft.spage=e51&rft.epage=e57&rft.pages=e51-e57&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1016/j.ahj.2009.06.008&rft_dat=%3Cproquest_cross%3E67668708%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1504612657&rft_id=info:pmid/19781403&rft_els_id=S0002870309004505&rfr_iscdi=true |